TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ

(Rutgers University) TAXIS Pharmaceuticals Inc., Rutgers, the State University of New Jersey, and the University of Medicine and Dentistry of New Jersey have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant bacterial infections.

source : www.eurekalert.org

Related News:

• Impact Of Ethnicity On Primary Treatment Choice And Mortality In Men With Prostate Cancer: Data From CaPSURE
• ACC: No Benefit from Ventricular Reconstruction (CME/CE)
• Inspire Announces Results From AZASITE(R) Phase 2 Blepharitis Trials And Plans To Continue Clinical Development In Anterior And Posterior Blepharitis
• Identifiication Of Brain Abnormalities That Result From Prenatal Meth Exposure Could Help Diagnose Affected Children
• How Cells Protect Themselves From Cancer
• News From Annals Of Internal Medicine, March 16, 2010
• Visually Impaired Students Benefit From New Teaching Tools
• AAOS: Burden of Injuries from ATVs Growing (CME/CE)
• Kidney Donors Suffer Few Ill-Effects From Life-Giving Act
• Infectious virus hidden in chromosomes can be passed from parents to children